
NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).

The FDA has sent Pfizer a Complete Response Letter about its rare disease drug tafamidis meglumine. The US regulator is …
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics

